Spots Global Cancer Trial Database for t790m
Every month we try and update this database with for t790m cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| T790M Mutation Positive 2nd Line STandard of cAre Registry | NCT02368990 | Non Small Cell ... | 18 Years - | AstraZeneca | ||
| Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC | NCT03543683 | Non-Small Cell ... Non-small Cell ... EGFR T790M | Osimertinib Aspirin | 18 Years - 75 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | NCT05498389 | Metastatic Lung... Advanced Lung N... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... EGFR Mutation-R... | EMB-01 Osimertinib | 18 Years - | Shanghai EpimAb Biotherapeutics Co., Ltd. | |
| Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC | NCT03046992 | EGFR Gene Mutat... | YH25448 | 20 Years - | Yuhan Corporation | |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive | NCT03812809 | NSCLC | BPI-7711 | 18 Years - | Beta Pharma, Inc. | |
| Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer) | NCT03053297 | Carcinoma, Non-... | Patient Reporte... | 18 Years - | AstraZeneca | |
| Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC | NCT03046992 | EGFR Gene Mutat... | YH25448 | 20 Years - | Yuhan Corporation | |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) | NCT03133546 | Non Small Cell ... | Osimertinib Bevacizumab | 18 Years - | ETOP IBCSG Partners Foundation | |
| TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy | NCT02186301 | Non-Small Cell ... | Rociletinib Mon... Erlotinib Mono-... | 18 Years - | Clovis Oncology, Inc. | |
| Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients | NCT01526928 | Locally Advance... | Rociletinib Rociletinib Rociletinib Rociletinib Rociletinib Rociletinib | 18 Years - | Clovis Oncology, Inc. | |
| EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | NCT05498389 | Metastatic Lung... Advanced Lung N... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... EGFR Mutation-R... | EMB-01 Osimertinib | 18 Years - | Shanghai EpimAb Biotherapeutics Co., Ltd. | |
| Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA | NCT03228277 | Non Small Cell ... | Olmutinib | 19 Years - | Konkuk University Medical Center | |
| Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) | NCT03133546 | Non Small Cell ... | Osimertinib Bevacizumab | 18 Years - | ETOP IBCSG Partners Foundation | |
| Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer | NCT02147990 | Non-small Cell ... | Rociletinib | 18 Years - | Clovis Oncology, Inc. | |
| TAURAS - T790 AURA ScreenFailure SOC Registry Study | NCT02405247 | Non Small Cell ... | Patient Reporte... | 18 Years - | AstraZeneca | |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer | NCT02147990 | Non-small Cell ... | Rociletinib | 18 Years - | Clovis Oncology, Inc. | |
| TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy | NCT02186301 | Non-Small Cell ... | Rociletinib Mon... Erlotinib Mono-... | 18 Years - | Clovis Oncology, Inc. | |
| A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer | NCT02789345 | Non-small Cell ... | Ramucirumab Necitumumab Osimertinib | 18 Years - | Eli Lilly and Company | |
| TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy | NCT02322281 | Non-small Cell ... | Rociletinib Pemetrexed or g... | 18 Years - | Clovis Oncology, Inc. | |
| Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer | NCT05517083 | Non Small Cell ... EGFR Gene Mutat... | Ultarthin bronc... | 20 Years - | Pusan National University Hospital | |
| Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) | NCT03133546 | Non Small Cell ... | Osimertinib Bevacizumab | 18 Years - | ETOP IBCSG Partners Foundation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
